Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275158 | 1.00 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4271916 | 1.00 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10384072 | 1.00 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4280442 | 1.00 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL1817035 | 1.00 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4275678 | 1.00 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL27815332 | 1.00 | DNM1 (0.55) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Bromide SCHEMBL5500592 | 0.98 | DNM1 (0.53) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL6577557 | 0.91 | DNM1 (0.43) | DNM1MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL3244710 | 0.89 | DNM1 (0.53) | DNM1MEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963982-B2 | CRISPR/RNA-guided nuclease systems and methods | EDITAS MEDICINE, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4126039-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION | BioNTech SE (DE) | 2023-02-08 | — | — | EP | disclosed |
| US-20210371858-A1 | METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS | BEAM THERAPEUTICS INC. (US) | 2021-12-02 | — | — | US | disclosed |
| WO-2021198258-A1 | TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION | BioNTech SE (DE) | 2021-10-07 | — | — | WO | disclosed |
| US-20200155606-A1 | CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS | EDITAS MEDICINE, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| EP-0954339-A2 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | Genzyme Corporation (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998002191-A2 | CATIONIC AMPHIPHILE COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES | GENZYME CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| US-4757144-A | Adding aqueous or methanolic solution of formaldehyde to mixture of primary or secondary amines, palladium or platinum catalyst | KAO CORPORATION (JP) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155606-A1 | CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS | ZFR, ADAR, RNGTT | DNM1 477/4885MEN1 2907/4885KMT2A 956/4885 |
| US-11963982-B2 | CRISPR/RNA-guided nuclease systems and methods | ZFR, ADAR, RNGTT | DNM1 477/4885MEN1 2907/4885KMT2A 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.